Ropivacaine is a local anesthetic used to numb specific areas of the body during surgery, dental procedures, or to relieve pain after certain medical procedures.[2] Naropin is currently approved and in use across 80 indications[4].[1]
Naropin is one of 822 small molecule programs targeting Total Knee Arthroplasty. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
348 competitors in Prostate Cancer
Naropin
Antiandrogen Therapy
Xaluritamig
Radium-223
Gallium Ga 68 Gozetotide
Androgen Deprivation Treatment
Antibiotic Prophylaxis
Trexall
Botox
Duragesic
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
May 1, 1998
NAROPIN
NDA NDA020533
Feb 9, 2000
NAROPIN
NDA NDA020533
Jun 22, 2000
NAROPIN
NDA NDA020533
Nov 2, 2000
NAROPIN
NDA NDA020533
Nov 14, 2000
NAROPIN
NDA NDA020533
Jul 17, 2002
NAROPIN
NDA NDA020533
Aug 11, 2004
NAROPIN
NDA NDA020533
Aug 8, 2006
NAROPIN
NDA NDA020533
Feb 19, 2010
NAROPIN
NDA NDA020533
Feb 19, 2010
NAROPIN
NDA NDA020533
Jan 4, 2011
NAROPIN
NDA NDA020533
Nov 9, 2012
NAROPIN
NDA NDA020533
Nov 15, 2012
NAROPIN
NDA NDA020533
Dec 26, 2012
NAROPIN
NDA NDA020533
Feb 16, 2013
NAROPIN
NDA NDA020533
Apr 21, 2013
NAROPIN
NDA NDA020533
Oct 29, 2014
NAROPIN
NDA NDA020533
Jun 6, 2016
NAROPIN
NDA NDA020533
Feb 15, 2018
NAROPIN
NDA NDA020533
Nov 2, 2018
NAROPIN
NDA NDA020533
Jun 15, 2022
NAROPIN
NDA NDA020533
Jun 28, 2022
NAROPIN
NDA NDA020533
Sources
Details
Patent Cliff
Nov 28, 2026
Earliest patent expiration — generic entry possible after this date